Trials / Completed
CompletedNCT01567085
Safety & Efficacy Of Eculizumab In The Prevention Of AMR In Sensitized Recipients Of A Kidney Transplant From A Deceased Donor
An Open-Label, Single-Arm, Multicenter Trial to Determine Safety and Efficacy of Eculizumab in the Prevention of Antibody Mediated Rejection (AMR) in Sensitized Recipients of a Kidney Transplant From a Deceased Donor.
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 80 (actual)
- Sponsor
- Alexion Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Primary Objective: To evaluate the safety and potential efficacy of eculizumab to prevent AMR in sensitized recipients of deceased donor kidney transplants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Eculizumab |
Timeline
- Start date
- 2012-08-29
- Primary completion
- 2015-06-11
- Completion
- 2017-05-24
- First posted
- 2012-03-30
- Last updated
- 2019-05-03
- Results posted
- 2019-05-03
Locations
15 sites across 6 countries: Australia, France, Italy, Spain, Sweden, United Kingdom
Source: ClinicalTrials.gov record NCT01567085. Inclusion in this directory is not an endorsement.